Founded Year

2017

About MedySapiens

MedySapiens provides genetic analysis test service to global medical institutes by applying Bio-Technology and Artificial Intelligence technologies in order to save lives and improve Quality of Life for rare disease patients. The firm's products consist of MedyNA (MedySapiens’ Neonatal Action panel, yet a tentative name planned for a trademark filing soon) and MedyCVi (MedySapiens’ Cloud for Variant interpretation).

MedySapiens Headquarter Location

Rm 113, SNU Research Park Main Center 1 Gwanak-ro, Gwanak-gu

Seoul, 08826,

South Korea

+82-10-7152-099

MedySapiens's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

MedySapiens's Products & Differentiation

See MedySapiens's products and how their products differentiate from alternatives and competitors

  • NEOseq_ACTION

    Panel, in other words combination of reagents. Designed to identify, isolate and amplify targeted 254 genes out of all human genes (usually 20~30k). These 254 selected genes are believed to be causing 220 "fairly common" rare diseases that have treatments, cures, medicine or remedy at least to alleviate pain etc.

    Differentiation

    Compared to WGS (Whole Genome Sequencing) or WES (Whole Exom Sequencing), which usually require mililiter level of blood, we only need microliters of blood in the form of DBS (Dried Blood Spot). WGS… 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Latest MedySapiens News

MedySapiens Diagnosed 200 Kinds of Neonatal Rare Diseases Using AI..“The Key Move in USA”

May 25, 2020

바이오스펙테이터 기사입력 : 2020-05-26 07:26|수정 : 2020-05-26 07:26 by Naeun Bong MedySapiens Developed the Platform Combining AI with Genomics..“Demonstrated 100% Accuracy in the Pilot Studies Conducted in Seoul National University Hospital" “… We intend to provide the clinical doctors with services that could enable them to make quick, accurate, and pertinent diagnoses of diseases within a week by exploiting Artificial intelligence(AI) and the database of genomics comprising 200-300 neonatal rare diseases with corresponding therapies for newborn babies admitted to the NICU …” President Kang Sang-gu, who founded MedySapiens in 2016, introduced its core platform enabled to facilitate the diagnosis of more than 200 rare genetic diseases as in the above statement. MedySapiens devised the diagnosis-assisting service, enabling clinical doctors to make quick, accurate, and definite diagnosis, by delivering the results of the analysis on actionable genes associated with 200 or more specified diseases within a week through exploiting single examination on a small amount of blood sample of neonates. Three Differentiable Points in Diagnosis of ‘Rare Genetic Diseases’ of MedySapiens MedySapiens currently promotes the business of diagnosis-assisting service manifested in three differentiable points by reflecting the highly expensive therapeutic agents and waiting time of approximately two to four weeks to the availability of results of diagnosis. Point ①The Design of NICU Panel Above all, MedySapiens collaborated with faculties in the Department of Pediatrics in Seoul National University Hospital, and designed the NICU Panel, ‘MedyCVi’, capable of screening, detecting, and analyzing genes associated with more than 200 kinds of diseases of higher prevalence. Point ② The Application of AI Technology MedySapiens applied the AI technology enabling the spontaneous assessment of pathogenicity of genetic mutation detected by the ‘MedyCVi’. Based on scores set by MedySapiens, the AI can distinguish genetic mutations into categories of VUS (variant of uncertain significance), benign, or pathogenic, etc. Point ③ ‘Web’ based Cloud MedySapiens elaborated the MedyCVi in the form of a Web-based cloud other than the ‘Linux’ system to improve the availability and convenience of users (clinical doctors). Thus, MedyCVi’s contribution to the development of the database, resulting from the convenient use and management of clinical doctors, was realized. 100% Accuracy in Analysis Achieved in the First and Second Pilot Studies ... “Prospective Study Plans Are Prepared for New Patients” MedySapiens managed the two pilot studies with the support from the Ministry of SMEs and Startups by exploiting the samples of patients admitted to the NICU in Seoul National University Hospital. The pilot tests were the blind tests designed to compare diagnoses with the results of diagnosis prepared by applying the NICU panel. MedySapiens accomplished 100% accuracy in the two pilot studies. Based on results obtained from the two pilot studies, MedySapiens intends to promote the prospective studies to be conducted in Seoul National University Hospital, Seoul National University Hospital in Bundang, Asan Medical Center, and Soonchunhyang University Hospital with new patients admitted to the NICU in each hospital. The practical objective of MedySapiens will be to make inroads into the American market. Since its founding in 2016, MedySapiens has maintained the relationship with a large General Hospital in California, USA, continuously, anticipating for the day of entering the American market, ‘Cardiovascular Analysis’, the First Mission of AI Technology ... Followed by the Smart Beauty and Smart Technology of Diagnosis Which Are in Progress MedySapiens also collaborated with the Department of Cardiology of Asan Medical Center in Seoul as the first project using AI Technology supported by the Ministry of SMEs and Startups for the study of analyzing cardiovascular diseases only with X-ray images. In the project, AI technology is supposed to detect lesions of cardiovascular diseases from the X-ray images and evaluate the resulting risks quantitatively. Besides, MedySapiens currently manages the ‘Smart Beauty’ project based on AI technology also supported by the Ministry of SMEs and Startups wherein the assessment of skin is matched to customized and corresponding cosmetic products. The project, ‘Smart Technology of Diagnosis’, capable of diagnosing diseases through exploiting the AI technology, will be launched in the future with the completion of digitalization of pathologic organs. by Naeun Bong press@bios.co.kr

You May Also Like

Everly Health Logo
Everly Health

Everly Health provides an e-commerce platform that enables customers to buy a variety of test kits online, collect their sample at home, and get informative results without visiting a lab or doctor's office. The platform offers various at-home lab tests including sexual health, thyroid, metabolism, men's health, and breast milk DHA testing, which the company is the exclusive provider of in the U.S.

E
Eugene

Eugene provides DNA testing and health information services through a mobile application.

OmeCare Logo
OmeCare

OmeCare provides physicians and their patients with genetic information to improve or maintain health and wellness. The company's mobile health applications merge artificial intelligence and deep learning with personal genetic information that provides personalized health and wellness guidance.

L
LunaPBC

LunaPBC is the creator of LunaDNA, a health and genomic data platform owned by its community of personal health information donors. LunaDNA empowers individuals to share their health data for medical research and the greater good of the community. As community owners in the LunaDNA platform, members share in the value created from health discoveries and medical breakthroughs.

Geneticure Logo
Geneticure

Geneticure is tackling the standard of care for chronic and dangerous diseases by providing new tools for Clinicians to personalize therapy based on the specific patient. The company uses pharmacogenomics to develop tests that clinicians use to help patients get better faster, and with less cost. Its post-diagnostic genetic tests ensure each patient receives only the fewest, effective medications for their unique genetics and saving unnecessary medications, visits and adverse events. Moving well beyond drug-metabolizing enzymes, the Geneticure patented panels examine the receptors, proteins, and organ systems fundamental to drug response. With a unique understanding for the integrative physiology of complex diseases and supported by strong clinical evidence, Geneticure takes personalized medicine to another level not found in healthcare today.

W
WeGene

WeGene is dedicated to providing consumer genetic testing and personalized healthcare services through intelligent hardware, offline services, and online communities. Its report consists of ancestry analysis, genetic disease and health risk information, nutritional genomics, athletigen and drug responses analysis. WeGene is also committed to working with researchers to dig deep into genome data to promote scientific research while also allowing users to further benefit from their own genome data.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.